full
border
#666666
http://www.lennonsearch.com/wp-content/themes/smartbox-installable/
https://www.lennonsearch.com/
#26ADE4
style3
Over 25 Years Of Expertise
828-403-6096

Archive for June, 2015

26
Jun

Bristol-Myers Squibb’s latest R&D reshuffle calls for a consolidated presence in Cambridge, MA’s booming Kendall Square, and the drugmaker has signed on to serve as anchor tenant in the area’s next big research facility, joining Big Pharma’s ongoing colonization of a biotech hotbed. …read more Source: Bristol-Myers is the next big tenant in biotech’s hottest […]

26
Jun

Cambridge, MA’s Seres Therapeutics pulled off an above-its-range IPO, grossing about $134 million to bankroll its work on drugs that change the weather in the gut to treat disease. …read more Source: Seres guts out a $134M IPO to fuel microbiome R&D     

25
Jun

The gene-sequencing pioneers at Illumina are planning to build a major new science center and European headquarters in the U.K.’s growing biotech hub in Cambridge. Illumina signed a lease on a 155,000-square-foot facility, designed to grow another 70,000 square feet as needed for future expansion. …read more Source: Genomics giant Illumina blueprints new Euro HQ/science […]

25
Jun

AbbVie has walked away from its claim to Biotest’s anti-CD4 monoclonal antibody, tregalizumab. The decision comes two months after Biotest posted Phase IIb data showing tregalizumab failed to outperform the placebo in terms of improvements to ACR20 scores. …read more Source: AbbVie hands back rights to Biotest’s RA drug after trial flop     

default
Loading posts...
link_magnifier
#5C5C5C
off
fadeInDown
loading
#5C5C5C
off